Yeleswaram Krishnaswamy 4
4 · Rapport Therapeutics, Inc. · Filed Mar 26, 2026
Research Summary
AI-generated summary of this filing
Rapport Therapeutics (RAPP) CDO Yeleswaram Sells 10,115 Shares
What Happened
- Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics (RAPP), sold 10,115 shares on March 25, 2026.
- The weighted-average sale price was $29.99 per share for a total proceeds of approximately $303,355. The reported sale type is "S" (sale), indicating a disposition of shares.
Key Details
- Transaction date: 2026-03-25; filing date: 2026-03-26 (timely filing).
- Price: weighted average $29.99; individual trades ranged from $29.90 to $30.18 (per footnote).
- Shares disposed: 10,115; proceeds ≈ $303,355.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnotes: F1 — sale was effected under a Rule 10b5-1 trading plan adopted December 10, 2025. F2 — price is a weighted average; reporting person will provide per-price breakdown on request.
- Transaction code: S = Sale.
Context
- The sale was executed under a pre-established 10b5-1 plan, which typically means the trades were pre-planned and not necessarily a reflection of the insider’s current view of the company.
- For retail investors, purchases often convey more direct insider confidence than scheduled sales; this filing documents a routine, pre-arranged disposition.
Insider Transaction Report
Form 4
Yeleswaram Krishnaswamy
Chief Development Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-03-25$29.99/sh−10,115$303,355→ 286,876 total
Footnotes (2)
- [F1]These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.90 to $30.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Signature
/s/ Troy Ignelzi, Attorney-in-Fact|2026-03-26